GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (STU:4AYB) » Definitions » Equity-to-Asset

Ablynx NV (STU:4AYB) Equity-to-Asset : 0.46 (As of Dec. 2017)


View and export this data going back to 2017. Start your Free Trial

What is Ablynx NV Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ablynx NV's Total Stockholders Equity for the quarter that ended in Dec. 2017 was €179.86 Mil. Ablynx NV's Total Assets for the quarter that ended in Dec. 2017 was €389.85 Mil. Therefore, Ablynx NV's Equity to Asset Ratio for the quarter that ended in Dec. 2017 was 0.46.

The historical rank and industry rank for Ablynx NV's Equity-to-Asset or its related term are showing as below:

STU:4AYB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11   Med: 0.53   Max: 0.81
Current: 0.46

During the past 12 years, the highest Equity to Asset Ratio of Ablynx NV was 0.81. The lowest was 0.11. And the median was 0.53.

STU:4AYB's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs STU:4AYB: 0.46

Ablynx NV Equity-to-Asset Historical Data

The historical data trend for Ablynx NV's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Equity-to-Asset Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.34 0.11 0.39 0.46

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.40 0.39 0.34 0.46

Competitive Comparison of Ablynx NV's Equity-to-Asset

For the Biotechnology subindustry, Ablynx NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ablynx NV's Equity-to-Asset falls into.



Ablynx NV Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ablynx NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Equity to Asset (A: Dec. 2017 )=Total Stockholders Equity/Total Assets
=179.856/389.848
=0.46

Ablynx NV's Equity to Asset Ratio for the quarter that ended in Dec. 2017 is calculated as

Equity to Asset (Q: Dec. 2017 )=Total Stockholders Equity/Total Assets
=179.856/389.848
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV  (STU:4AYB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ablynx NV Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV (STU:4AYB) Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (STU:4AYB) Headlines

No Headlines